The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London open: Shares rise as Avis takeover stokes M&A excitement

Tue, 14th Jun 2011 08:32

London's leading share index is posting strong decent growth this morning in contrast to recent sluggishness, but the excitement is in the FTSE 250 with Avis Europe soaring on news the Avis car hire brand is set to return to single ownership after US operator Avis Budget launched an agreed bid.Avis Budget will offer 315p cash for each Avis Europe share in a deal that values the UK listed company at around £636m. The mid-market price of Avis Europe on the day before the bid was announced was 196.6p.In the FTSE 100, supermarket giant Tesco is weaker after failing to return to sales growth in the UK. In the 13 weeks to 28 May, Tesco's UK like-for-like sales excluding petrol and the impact of VAT were down by 0.1% from the same period the previous year, in line with analysts' predictions, having contracted over the previous quarter. Total sales grew by 7% including petrol and VAT.Another FTSE 100 giant, commodity trading giant Glencore, demonstrated the strength of the markets that propelled it straight into the FTSE 100 after its flotation, revealing a 39% rise in revenues over the first quarter in its first interim management statement as a listed company. Its shares are lower too.Drug giant GlaxoSmithKline has taken another step towards increasing its presence in emerging markets, with the acquisition of the remaining 51% interest in a joint venture established in China to develop 'flu vaccines. It paid Shenzhen Neptunus Interlong Bio-Technique £24m for the stake in the joint venture, which is called Shenzhen GSK-Neptunus Biologicals (GSKNB). Glaxo will become the sole owner of the JV after the agreement is approved by the Chinese authorities. Oilfield services firm Wood Group has extended its contract with TAQA Bratani Limited, the energy company that is 51% owned by Abu Dhabi Water and Electricity Authority, for a further five years.AIM-listed asset finance provider to small and medium enterprise (SMEs) 1pm moved up more than 25% after saying it will announce a return to profitability for the full year following improved trading.FTSE 100 - RisersSchroders (SDR) 1,568.00p +2.75%Schroders (Non-Voting) (SDRC) 1,302.00p +2.04%Essar Energy (ESSR) 438.60p +1.50%IMI (IMI) 1,026.00p +1.48%Barclays (BARC) 264.15p +1.46%Weir Group (WEIR) 2,060.00p +1.43%BHP Billiton (BLT) 2,312.50p +1.43%Vedanta Resources (VED) 2,021.00p +1.40%Rio Tinto (RIO) 4,162.50p +1.39%Anglo American (AAL) 2,937.50p +1.28%FTSE 100 - FallersGlencore International (GLEN) 514.00p -1.80%Tesco (TSCO) 402.05p -1.26%Johnson Matthey (JMAT) 1,978.00p -0.70%Imperial Tobacco Group (IMT) 2,043.00p -0.63%Eurasian Natural Resources Corp. (ENRC) 772.00p -0.58%Carnival (CCL) 2,248.00p -0.27%Scottish & Southern Energy (SSE) 1,381.00p -0.22%Admiral Group (ADM) 1,712.00p -0.17%Morrison (Wm) Supermarkets (MRW) 295.40p -0.14%Randgold Resources Ltd. (RRS) 4,744.00p -0.13%FTSE 250 - RisersAvis Europe (AVE) 310.80p +58.09%AZ Electronic Materials SA (WI) (AZEM) 318.40p +3.44%Howden Joinery Group (HWDN) 109.20p +2.34%Regus (RGU) 104.70p +2.25%Chemring Group (CHG) 669.00p +2.14%Helical Bar (HLCL) 260.00p +2.12%Cookson Group (CKSN) 663.00p +2.08%Stobart Group Ltd. (STOB) 140.00p +2.04%Elementis (ELM) 161.10p +1.90%Sports Direct International (SPD) 228.20p +1.88%FTSE 250 - FallersLamprell (LAM) 348.00p -9.14%Centamin Egypt Ltd. (CEY) 113.50p -2.24%Telecom Plus (TEP) 603.00p -1.71%Kofax (KFX) 480.00p -1.44%Punch Taverns (PUB) 71.50p -1.38%Berendsen (BRSN) 491.90p -1.03%Exillon Energy (EXI) 415.10p -1.03%Scottish Inv Trust (SCIN) 495.30p -0.90%African Barrick Gold (ABG) 402.90p -0.76%BH Global Ltd. GBP Shares (BHGG) 1,093.00p -0.64%
More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.